Standard Review for Biogen's BG-12 Zacks.com Meanwhile, Biogen and partner Abbott (ABT - Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous injection for ... |
